With our data, we pave the opportunity to design and validate PHD1-specific inhibitors in colorectal cancer patients carrying wild-type or DNA contact mutant p53 aiming to increase their sensitivity to currently used chemotherapeutic treatments. Here, TP53 is linked to colorectal cancer.